Base de dados : MEDLINE
Pesquisa : D12.776.964.775.350.362.500 [Categoria DeCS]
Referências encontradas : 3238 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 324 ir para página                         

  1 / 3238 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28891315
[Au] Autor:Kammari K; Devaraya K; Bommakanti A; Kondapi AK
[Ad] Endereço:Department of Biotechnology & Bioinformatics, School of Life Sciences, University of Hyderabad.
[Ti] Título:Development of pyridine dicoumarols as potent anti HIV-1 leads, targeting HIV-1 associated topoisomeraseIIß kinase.
[So] Source:Future Med Chem;9(14):1597-1609, 2017 Sep.
[Is] ISSN:1756-8927
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIM: A structural study of a series of pyridine dicoumarol derivatives with potential activity against a novel Topoisomerase IIß kinase which was identified in the HIV-1 viral lysate, compounds were designed and synthesized based on a 3D-QSAR study. MATERIALS & METHODS: Based on QSAR model we have designed and synthesized a series of pyridine dicoumarol derivatives and characterized by spectral studies, all the molecules are biologically evaluated by kinase assay, cytotoxicity assay, ELISA and PCR method. RESULT: We demonstrated the achievement of water soluble disodium pyridine dicoumarate derivatives showing high anti-HIV-1 activity (IC <25 nM) which provides a crucial point for further development of pyridine dicoumarol series as HIV-1-associated topoisomerase IIß kinase inhibitors for clinical application against AIDS. CONCLUSION: A new class of anti-HIV-1 lead compounds have been designed and tested. Further studies would result in development of  novel and potential drugs.
[Mh] Termos MeSH primário: DNA Topoisomerases Tipo II/metabolismo
Proteínas de Ligação a DNA/metabolismo
Dicumarol/metabolismo
HIV-1/enzimologia
Inibidores da Topoisomerase II/metabolismo
[Mh] Termos MeSH secundário: Fármacos Anti-HIV/química
Fármacos Anti-HIV/metabolismo
Fármacos Anti-HIV/toxicidade
Linhagem Celular
Sobrevivência Celular/efeitos dos fármacos
Proteínas de Ligação a DNA/antagonistas & inibidores
Dicumarol/química
Dicumarol/farmacologia
Desenho de Drogas
Ensaio de Imunoadsorção Enzimática
Proteína do Núcleo p24 do HIV/antagonistas & inibidores
Proteína do Núcleo p24 do HIV/metabolismo
HIV-1/efeitos dos fármacos
Seres Humanos
Piridinas/química
Relação Quantitativa Estrutura-Atividade
Inibidores da Topoisomerase II/química
Inibidores da Topoisomerase II/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (DNA-Binding Proteins); 0 (HIV Core Protein p24); 0 (Pyridines); 0 (Topoisomerase II Inhibitors); 7QID3E7BG7 (Dicumarol); EC 5.99.1.3 (DNA Topoisomerases, Type II); NH9L3PP67S (pyridine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170912
[St] Status:MEDLINE
[do] DOI:10.4155/fmc-2017-0091


  2 / 3238 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28432147
[Au] Autor:Gutjahr A; Papagno L; Nicoli F; Lamoureux A; Vernejoul F; Lioux T; Gostick E; Price DA; Tiraby G; Perouzel E; Appay V; Verrier B; Paul S
[Ad] Endereço:InvivoGen, 31400 Toulouse, France.
[Ti] Título:Cutting Edge: A Dual TLR2 and TLR7 Ligand Induces Highly Potent Humoral and Cell-Mediated Immune Responses.
[So] Source:J Immunol;198(11):4205-4209, 2017 Jun 01.
[Is] ISSN:1550-6606
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:TLR agonists are currently being developed and tested as adjuvants in various formulations to optimize the immunogenicity and efficacy of vaccines. The aim of this study was to evaluate the immunostimulatory properties of a novel compound incorporating covalently linked moieties designed to stimulate both TLR2 and TLR7. This dual TLR2/TLR7 agonist induced the maturation of dendritic cells and primed substantial populations of cytolytic and highly polyfunctional effector CD8 T cells in vitro, and safely potentiated the immunogenic properties of a nanoparticulate Ag in vivo, eliciting humoral responses with a balanced T 1/T 2 profile in mice. Collectively, these data reveal the potential utility of chimeric adjuvants with synergistic activities mediated via TLRs.
[Mh] Termos MeSH primário: Adjuvantes Imunológicos
Imunidade Celular
Imunidade Humoral
Glicoproteínas de Membrana/agonistas
Glicoproteínas de Membrana/imunologia
Receptor 2 Toll-Like/agonistas
Receptor 2 Toll-Like/imunologia
Receptor 7 Toll-Like/agonistas
Receptor 7 Toll-Like/imunologia
[Mh] Termos MeSH secundário: Animais
Formação de Anticorpos
Linfócitos T CD8-Positivos/imunologia
Diferenciação Celular
Citocinas
Células Dendríticas/imunologia
Células Dendríticas/fisiologia
Proteína do Núcleo p24 do HIV/administração & dosagem
Proteína do Núcleo p24 do HIV/imunologia
Ligantes
Camundongos
Camundongos Endogâmicos C57BL
Nanopartículas
Proteínas Recombinantes de Fusão/imunologia
Vacinação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Cytokines); 0 (HIV Core Protein p24); 0 (Ligands); 0 (Membrane Glycoproteins); 0 (Recombinant Fusion Proteins); 0 (Tlr2 protein, mouse); 0 (Tlr7 protein, mouse); 0 (Toll-Like Receptor 2); 0 (Toll-Like Receptor 7)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170423
[St] Status:MEDLINE
[do] DOI:10.4049/jimmunol.1602131


  3 / 3238 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28222792
[Au] Autor:Karabaev BB; Beisheeva NJ; Satybaldieva AB; Ismailova AD; Pessler F; Akmatov MK
[Ad] Endereço:Republican Blood Centre, Bishkek, Kyrgyzstan, Chingiz Aitmatov Ave 60, 720044, Bishkek, Kyrgyzstan.
[Ti] Título:Seroprevalence of hepatitis B, hepatitis C, human immunodeficiency virus, Treponema pallidum, and co-infections among blood donors in Kyrgyzstan: a retrospective analysis (2013-2015).
[So] Source:Infect Dis Poverty;6(1):45, 2017 Feb 21.
[Is] ISSN:2049-9957
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Post-Soviet Kyrgyzstan has experienced a major surge in blood-borne infections, but data from adequately powered, up-to-date studies are lacking. We thus examined a) the seroprevalences of hepatitis B virus surface antigen (HBsAg), HIV-1 p24 antigen and antibodies against hepatitis C virus (anti-HCV), human immunodeficiency viruses (anti-HIV-1/2, HIV-1 group O), and Treponema pallidum among blood donors in Kyrgyzstan and assess their distribution according to sex, age, and provinces of residence; b) trends in the respective seroprevalences; and c) co-infection rates among the pathogens studied. METHODS: Serological screening was performed on 37 165 blood donors at the Republican Blood Centre in Bishkek, Kyrgyzstan, between January 2013 and December 2015. We applied poststratification weights to control for sampling bias and used logistic regression analyses to examine the association of seropositivity and co-infections with sex, age, provinces of residence, and year of blood donation. RESULTS: Twenty nine thousand and one hundred forty-five (78%) donors were males and 8 020 (22%) were females. The median age was 27 years (range: 18 - 64). The prevalences of HBsAg, anti-HCV, HIV (p24 Ag and anti-HIV), and anti-T. pallidum were 3.6% (95%CI: 3.4 - 3.8%), 3.1% (3.0 - 3.3%), 0.78% (0.69 - 0.87%), and 3.3% (3.1 - 3.5%), respectively. Males were more likely to be seropositive for HBsAg than females (OR: 1.63; 95%CI: 1.40 - 1.90), but less likely to be seropositive for anti-HCV (0.85; 0.74 - 0.98) and HIV (0.65; 0.49 - 0.85). Prevalences were lower in the capital than in the other provinces. There was a decreasing trend in the seroprevalences of HBsAg, anti-HCV, and anti-T. pallidum from 2012 to 2015 (P-value for trend, P = 0.01, P < 0.0001, P < 0.0001, respectively), while the seroprevalence of HIV increased (P = 0.049). One hundred eighty donors (0.48%) were seropositive for multiple infections. The highest co-infection rate was observed between anti-T. pallidum and HBsAg (6.0%), followed by anti-HCV and anti-T. pallidum (5.2%), and HIV and anti-HCV (4.9%). CONCLUSIONS: The data suggest that Kyrgyzstan can be reclassified from high to lower-intermediate HBsAg endemicity, whereas the high HIV prevalence with a rising trend is an alarming finding that needs to be urgently addressed by public health authorities. The observed co-infections suggest common risk factors but also common preventive interventions.
[Mh] Termos MeSH primário: Doadores de Sangue
Coinfecção/epidemiologia
Infecções por HIV/epidemiologia
Hepatite B/epidemiologia
Hepatite C/epidemiologia
Sífilis/epidemiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Anticorpos Antibacterianos/sangue
Anticorpos Antivirais/sangue
Ensaio de Imunoadsorção Enzimática
Feminino
Proteína do Núcleo p24 do HIV/sangue
Infecções por HIV/imunologia
Infecções por HIV/virologia
Soroprevalência de HIV
HIV-1/imunologia
Hepacivirus/imunologia
Hepatite B/imunologia
Hepatite B/virologia
Antígenos de Superfície da Hepatite B/sangue
Vírus da Hepatite B/imunologia
Hepatite C/imunologia
Hepatite C/virologia
Anticorpos Anti-Hepatite C/sangue
Seres Humanos
Quirguistão/epidemiologia
Masculino
Programas de Rastreamento
Meia-Idade
Estudos Retrospectivos
Estudos Soroepidemiológicos
Sífilis/imunologia
Sífilis/microbiologia
Treponema pallidum/imunologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Bacterial); 0 (Antibodies, Viral); 0 (HIV Core Protein p24); 0 (Hepatitis B Surface Antigens); 0 (Hepatitis C Antibodies)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170306
[Lr] Data última revisão:
170306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170223
[St] Status:MEDLINE
[do] DOI:10.1186/s40249-017-0255-9


  4 / 3238 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28199410
[Au] Autor:Kosaka PM; Pini V; Calleja M; Tamayo J
[Ad] Endereço:IMM-Instituto de Microelectrónica de Madrid (CNM-CSIC), Isaac Newton, 8, PTM, Tres Cantos, Madrid, Spain.
[Ti] Título:Ultrasensitive detection of HIV-1 p24 antigen by a hybrid nanomechanical-optoplasmonic platform with potential for detecting HIV-1 at first week after infection.
[So] Source:PLoS One;12(2):e0171899, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Early detection of HIV infection is the best way to prevent spread of the disease and to improve the efficiency of the antiretroviral therapy. Nucleic acid amplification tests (NAAT) have become the gold-standard for detecting low-concentrations of the virus in blood. However, these methods are technically demanding and cost-prohibitive in developing countries. Immunoassays are more affordable and can be more easily adapted for point-of-care diagnosis. However, the sensitivity so far of these methods has been too low. We here report the development of a sandwich immunoassay that combines nanomechanical and optoplasmonic transduction methods for detecting the HIV-1 capsid antigen p24 in human serum. The immunoreactions take place on the surface of a compliant microcantilever where gold nanoparticles are used as both mechanical and plasmonic labels. The microcantilever acts as both a mechanical resonator and an optical cavity for the transduction of the mechanical and plasmonic signals. The limit of detection of the immunoassay is 10-17 g/mL that is equivalent to one virion in 10 mL of plasma. This is 5 orders of magnitude better than last generation of approved immunoassays and 2 orders of magnitude better than NAAT. This technology meets the demands to be produced en masse at low cost and the capability for miniaturization to be used at the point-of-care.
[Mh] Termos MeSH primário: Proteína do Núcleo p24 do HIV/sangue
Infecções por HIV/diagnóstico
HIV-1/metabolismo
Imunoensaio/métodos
Nanotecnologia
[Mh] Termos MeSH secundário: Ouro/química
Seres Humanos
Imunoensaio/instrumentação
Limite de Detecção
Masculino
Nanopartículas Metálicas/química
Microscopia
Sistemas Automatizados de Assistência Junto ao Leito
Sensibilidade e Especificidade
Vírion/química
Vírion/isolamento & purificação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (HIV Core Protein p24); 7440-57-5 (Gold)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170828
[Lr] Data última revisão:
170828
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170216
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0171899


  5 / 3238 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28077644
[Au] Autor:Passaes CP; Bruel T; Decalf J; David A; Angin M; Monceaux V; Muller-Trutwin M; Noel N; Bourdic K; Lambotte O; Albert ML; Duffy D; Schwartz O; Sáez-Cirión A; ANRS RHIVIERA Consortium
[Ad] Endereço:Institut Pasteur, Unité HIV, Inflammation et Persistance, Départements de Virologie et Immunologie, Paris, France.
[Ti] Título:Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents.
[So] Source:J Virol;91(6), 2017 03 15.
[Is] ISSN:1098-5514
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The existence of HIV reservoirs in infected individuals under combined antiretroviral therapy (cART) represents a major obstacle toward cure. Viral reservoirs are assessed by quantification of HIV nucleic acids, a method which does not discriminate between infectious and defective viruses, or by viral outgrowth assays, which require large numbers of cells and long-term cultures. Here, we used an ultrasensitive p24 digital assay, which we report to be 1,000-fold more sensitive than classical enzyme-linked immunosorbent assays (ELISAs) in the quantification of HIV-1 Gag p24 production in samples from HIV-infected individuals. Results from ultrasensitive p24 assays were compared to those from conventional viral RNA reverse transcription-quantitative PCR (RT-qPCR)-based assays and from outgrowth assay readout by flow cytometry. Using serial dilutions and flow-based single-cell sorting, we show that viral proteins produced by a single infected cell can be detected by the ultrasensitive p24 assay. This unique sensitivity allowed the early (as soon as day 1 in 43% of cases) and more efficient detection and quantification of p24 in phytohemagglutinin-L (PHA)-stimulated CD4 T cells from individuals under effective cART. When seven different classes of latency reversal agents (LRA) in resting CD4 T cells from HIV-infected individuals were tested, the ultrasensitive p24 assay revealed differences in the extent of HIV reactivation. Of note, HIV RNA production was infrequently accompanied by p24 protein production (19%). Among the drugs tested, prostratin showed a superior capacity in inducing viral protein production. In summary, the ultrasensitive p24 assay allows the detection and quantification of p24 produced by single infected CD4 T cells and provides a unique tool to assess early reactivation of infectious virus from reservoirs in HIV-infected individuals. The persistence of HIV reservoirs in infected individuals under effective antiretroviral treatment represents a major obstacle toward cure. Different methods to estimate HIV reservoirs exist, but there is currently no optimal assay to measure HIV reservoirs in HIV eradication interventions. In the present study, we report an ultrasensitive digital ELISA platform for quantification of the HIV-1 protein p24. This method was employed to assess the early reactivation of infectious virus from reservoirs in HIV-1-infected individuals. We found that viral proteins produced by a single infected cell can be detected by an ultrasensitive p24 assay. This unprecedented resolution showed major advantages in comparison to other techniques currently used to assess viral replication in reactivation studies. In addition, such a highly sensitive assay allows discrimination of drug-induced reactivation of productive HIV based on protein expression. The present study heralds new opportunities to evaluate the HIV reservoir and the efficacy of drugs used to target it.
[Mh] Termos MeSH primário: Proteína do Núcleo p24 do HIV/análise
HIV-1/efeitos dos fármacos
HIV-1/fisiologia
Virologia/métodos
Ativação Viral/efeitos dos fármacos
Latência Viral/efeitos dos fármacos
[Mh] Termos MeSH secundário: Linfócitos T CD4-Positivos/virologia
Infecções por HIV/virologia
Seres Humanos
Sensibilidade e Especificidade
[Pt] Tipo de publicação:COMPARATIVE STUDY; EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (HIV Core Protein p24)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170828
[Lr] Data última revisão:
170828
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170113
[St] Status:MEDLINE


  6 / 3238 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28073435
[Au] Autor:He X; Wang W; Xu K; Feng X; Zeng Y
[Ad] Endereço:State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052, China.
[Ti] Título:Evaluation of the efficacy of a therapeutic HIV vaccine by in vitro stimulation assay.
[So] Source:Cell Immunol;313:67-71, 2017 Mar.
[Is] ISSN:1090-2163
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A novel method for HIV vaccine efficacy evaluation was established and the experimental conditions optimized. This novel method was then applied to determine whether a recombinant adenovirus type 5 HIV therapeutic vaccine expressing Gag antigen (Ad5-HIVgag) could stimulate HIV-specific cellular responses in vitro. The results indicated that HIV-specific IFN-gama production lymphocytes were induced by the Ad5-HIVgag vaccine. Compared with other methods, this in vitro stimulation method is safe and time-efficient, and the result is more intuitive. It has the potential to be regarded as a supplement to other methods for evaluating the IFN-gamma production by PBMCs to HIV vaccination.
[Mh] Termos MeSH primário: Vacinas contra a AIDS/farmacologia
Infecções por HIV/terapia
HIV-1/imunologia
Imunoterapia/métodos
Linfócitos T/imunologia
[Mh] Termos MeSH secundário: Vacinas contra a AIDS/genética
Vacinas contra Adenovirus
Adolescente
Adulto
Células Cultivadas
China
ELISPOT
Feminino
Proteína do Núcleo p24 do HIV/genética
Infecções por HIV/imunologia
Seres Humanos
Interferon gama/metabolismo
Ativação Linfocitária
Masculino
Meia-Idade
Fragmentos de Peptídeos/genética
Adulto Jovem
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (AIDS Vaccines); 0 (Adenovirus Vaccines); 0 (HIV Core Protein p24); 0 (Peptide Fragments); 82115-62-6 (Interferon-gamma)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170705
[Lr] Data última revisão:
170705
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170112
[St] Status:MEDLINE


  7 / 3238 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28060886
[Au] Autor:Meggi B; Bollinger T; Mabunda N; Vubil A; Tobaiwa O; Quevedo JI; Loquiha O; Vojnov L; Peter TF; Jani IV
[Ad] Endereço:Instituto Nacional de Saúde, Maputo, Mozambique.
[Ti] Título:Point-Of-Care p24 Infant Testing for HIV May Increase Patient Identification despite Low Sensitivity.
[So] Source:PLoS One;12(1):e0169497, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The long delay in returning test results during early infant diagnosis of HIV (EID) often causes loss-to-follow-up prior to antiretroviral treatment (ART) initiation in resource-limited settings. A point-of-care (POC) test may help overcome these challenges. We evaluated the performance of the LYNX p24 Antigen POC test in Mozambique. 879 HIV-exposed infants under 18 months of age were enrolled consecutively at three primary healthcare clinics (PHC). Lancet heel-drawn blood was tested on-site by nurses using a prototype POC test for HIV Gag p24 antigen detection. Results of POC testing were compared to laboratory-based nucleic acid testing on dried blood spots. A comparison of the effect of sensitivity and timely test results return on successful diagnosis by POC and laboratory-based platforms was also calculated. The sensitivity and specificity of the LYNX p24 Ag test were 71.9%; (95% confidence interval [CI]: 58.5-83.0%) and 99.6% (95% CI: 98.9-99.9%), respectively. The predictive value of positive and negative tests were 93.2% (95% CI: 81.3-98.6%) and 97.9% (95% CI: 96.8-98.8%), respectively. Overall agreement was high (Cohen Kappa = 0.80; 95% CI: 0.71-0.89). Despite its lower sensitivity, the POC test had the potential to provide test results to up to 81% more patients compared to the laboratory-based test. This prototype POC p24 assay was feasible for use in PHCs but demonstrated low sensitivity for HIV detection. POC EID technologies that perform below standard recommendations may still be valuable diagnostic tools in settings with inefficient EID networks.
[Mh] Termos MeSH primário: Proteína do Núcleo p24 do HIV
Infecções por HIV/diagnóstico
HIV-1
Testes Imediatos
[Mh] Termos MeSH secundário: Fármacos Anti-HIV/uso terapêutico
Pré-Escolar
Estudos Transversais
Diagnóstico Precoce
Feminino
Proteína do Núcleo p24 do HIV/imunologia
Infecções por HIV/tratamento farmacológico
Infecções por HIV/epidemiologia
Infecções por HIV/imunologia
HIV-1/imunologia
Seres Humanos
Lactente
Recém-Nascido
Masculino
Moçambique/epidemiologia
Testes Imediatos/normas
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
Padrão de Cuidado
Fluxo de Trabalho
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (HIV Core Protein p24)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170815
[Lr] Data última revisão:
170815
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170107
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0169497


  8 / 3238 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27272704
[Au] Autor:Fitzgerald N; Cross M; O'Shea S; Fox J
[Ad] Endereço:Department of Genito-Urinary Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.
[Ti] Título:Diagnosing acute HIV infection at point of care: a retrospective analysis of the sensitivity and specificity of a fourth-generation point-of-care test for detection of HIV core protein p24.
[So] Source:Sex Transm Infect;93(2):100-101, 2017 Mar.
[Is] ISSN:1472-3263
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Detection of acute HIV infection is vital in preventing onward transmission. HIV point-of-care testing (POCT) has improved uptake of HIV testing but has been limited to third-generation assays, which only detect chronic HIV infection. Previous evaluation of the fourth-generation Alere Determine HIV-1/2 Ag/Ab Combo POCT showed only 50% sensitivity for HIV core protein p24 (p24 antigen) detection, which is suboptimal for diagnosis of acute HIV infection with limited advantage over third-generation POCT. We aimed to assess the sensitivity of the new Alere HIV Combo POCT to detect acute HIV infection. METHODS: Stored samples in samples already identified as p24-positive using standard-of-care fourth-generation assays were randomly selected alongside groups of antibody-positive samples and HIV-negative samples. Each sample was tested using the new Alere POCT according to manufacturer's instructions. Sensitivity and specificity were then calculated. RESULTS: The Alere HIV Combo POCT test demonstrated 88% sensitivity 95% CI (78% to 98%) and 100% specificity 95% CI (99.7% to 100%) for detection of p24 antigen. CONCLUSIONS: This new POCT shows improved sensitivity for detection of p24 antigen and may be of value for clinical use in detecting acute HIV infection. Further evaluation of its use in a clinical setting is still required.
[Mh] Termos MeSH primário: Anticorpos Anti-HIV/sangue
Proteína do Núcleo p24 do HIV/sangue
Infecções por HIV/diagnóstico
HIV-1/imunologia
Técnicas Imunoenzimáticas/métodos
Testes Imediatos
[Mh] Termos MeSH secundário: Anticorpos Anti-HIV/análise
Proteína do Núcleo p24 do HIV/análise
Seres Humanos
Programas de Rastreamento
Kit de Reagentes para Diagnóstico
Estudos Retrospectivos
Sensibilidade e Especificidade
Reino Unido
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (HIV Antibodies); 0 (HIV Core Protein p24); 0 (Reagent Kits, Diagnostic)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170607
[Lr] Data última revisão:
170607
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160609
[St] Status:MEDLINE
[do] DOI:10.1136/sextrans-2015-052491


  9 / 3238 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27264875
[Au] Autor:Ogasawara N; Takano KI; Kobayashi H; Kikuchi K; Matsumiya H; Yoshioka I; Himi T
[Ad] Endereço:Department of Otorhinolaryngology, Sapporo Medical University School of Medicine, Sapporo, Japan; Department of Otorhinolaryngology, Obihiro Kousei Hospital, Japan. Electronic address: ogasawara.n@sapmed.ac.jp.
[Ti] Título:HIV-associated cystic lesions of the parotid gland.
[So] Source:Auris Nasus Larynx;44(1):126-130, 2017 Feb.
[Is] ISSN:1879-1476
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:We present two cases of an HIV-associated parotid gland cyst. One case was a 36-year-old HIV infected woman. She was diagnosed with HIV infection and presented with slowly enlarged parotid gland cysts together with elevation of HIV viral RNA copies/mL in her serum. She was performed parotid gland biopsy under the general anesthesia. The histopathologic analysis revealed negative HIV p24-antigen in her parotid gland tissue. The other case was a 43-year-old man found his parotid gland swelling shortly after highly active antiretroviral therapy (HAART). He was diagnosed with HIV infection 2 years previously. He had started HAART several days before. He showed exceeding elevation of IgE in his serum. We treated him with medication using anti-histamic drugs for his cyst. A computed tomography scan revealed a complete response of his parotid gland cyst 4 weeks after the medication. His serum IgE level was decreased to half of the level before the medication. These findings suggested that the parotid gland swelling associated with HIV was due to various factors including immune reconstitution inflammatory syndrome (IRIS). In case such a parotid gland swelling, we could avoid invasive treatments.
[Mh] Termos MeSH primário: Cistos/imunologia
Infecções por HIV/imunologia
Síndrome Inflamatória da Reconstituição Imune/imunologia
Imunoglobulina E/imunologia
Doenças Parotídeas/imunologia
[Mh] Termos MeSH secundário: Adulto
Terapia Antirretroviral de Alta Atividade
Cistos/complicações
Cistos/diagnóstico por imagem
Cistos/tratamento farmacológico
Feminino
Proteína do Núcleo p24 do HIV/metabolismo
Infecções por HIV/complicações
Infecções por HIV/tratamento farmacológico
Infecções por HIV/metabolismo
Antagonistas dos Receptores Histamínicos/uso terapêutico
Seres Humanos
Masculino
Doenças Parotídeas/complicações
Doenças Parotídeas/diagnóstico por imagem
Doenças Parotídeas/tratamento farmacológico
RNA Viral/metabolismo
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (HIV Core Protein p24); 0 (Histamine Antagonists); 0 (RNA, Viral); 37341-29-0 (Immunoglobulin E)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170723
[Lr] Data última revisão:
170723
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160607
[St] Status:MEDLINE


  10 / 3238 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27998072
[Au] Autor:Sepúlveda-Crespo D; Vacas-Córdoba E; Márquez-Miranda V; Araya-Durán I; Gómez R; Mata FJ; González-Nilo FD; Muñoz-Fernández MÁ
[Ad] Endereço:Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Spanish HIV-HGM BioBank , Madrid 28007, Spain.
[Ti] Título:Effect of Several HIV Antigens Simultaneously Loaded with G2-NN16 Carbosilane Dendrimer in the Cell Uptake and Functionality of Human Dendritic Cells.
[So] Source:Bioconjug Chem;27(12):2844-2849, 2016 Dec 21.
[Is] ISSN:1520-4812
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Dendrimers are highly branched, star-shaped, and nanosized polymers that have been proposed as new carriers for specific HIV-1 peptides. Dendritic cells (DCs) are the most-potent antigen-presenting cells that play a major role in the development of cell-mediated immunotherapy due to the generation and regulation of adaptive immune responses against HIV-1. This article reports on the associated behavior of two or three HIV-derived peptides simultaneously (p24/gp160 or p24/gp160/NEF) with cationic carbosilane dendrimer G2-NN16. We have found that (i) immature DCs (iDCs) and mature (mDCs) did not capture efficiently HIV peptides regarding the uptake level when cells were treated with G2-NN16-peptide complex alone; (ii) the ability of DCs to migrate was not depending on the peptides presence; and (iii) with the use of molecular dynamic simulation, a mixture of peptides decreased the cell uptake of the other peptides (in particular, NEF hinders the binding of more peptides and is especially obstructing of the binding of gp160 to G2-NN16). The results suggest that G2-NN16 cannot be considered as an alternative carrier for delivering two or more HIV-derived peptides to DCs.
[Mh] Termos MeSH primário: Dendrímeros/química
Células Dendríticas/efeitos dos fármacos
Antígenos HIV/química
Silanos/química
[Mh] Termos MeSH secundário: Dendrímeros/farmacocinética
Antígenos HIV/farmacologia
Proteína do Núcleo p24 do HIV/química
Proteína gp160 do Envelope de HIV/química
Seres Humanos
Simulação de Dinâmica Molecular
Silanos/farmacocinética
Eletricidade Estática
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (2G-NN16); 0 (Dendrimers); 0 (HIV Antigens); 0 (HIV Core Protein p24); 0 (HIV Envelope Protein gp160); 0 (Silanes); 0 (carbosilane)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170605
[Lr] Data última revisão:
170605
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161222
[St] Status:MEDLINE
[do] DOI:10.1021/acs.bioconjchem.6b00623



página 1 de 324 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde